Source disclosure: February 20, 2026
RaQualia Pharma Inc. [4579.T]
TOKYO, Feb 20 (Pulse News Wire) – RaQualia Pharma Inc. (4579.T) announced today that its licensee, AskAt Co., Ltd., has terminated the licensing agreement for the CB2 agonist compound RQ202,730/AAT-730/OCT461,201 with Oxford Cannabinoid Technologies Ltd.
The termination was due to OCT's breach of contract, not development issues. In November 2015, RaQualia entered into a rights purchase agreement with AskAt for the CB2 agonist, transferring intellectual property rights and retaining royalties on future revenue generated by AskAt. In July 2023, OCT initiated Phase I clinical trials in the UK for the treatment of chemotherapy-induced peripheral neuropathy (CIPN).
Despite the termination, AskAt plans to continue developing the drug and seek new partners. RaQualia stated it will maintain strong collaboration with AskAt, providing ongoing support for development and licensing efforts to enhance patient quality of life. The company noted there would be no impact on its fiscal year ending December 31, 2026 (January 1, 2026 to December 31, 2026).
AI-translated content. 🟢 Confidence: High See terms • Original filing